INTRODUCTION
Cannabinoid receptors are part of an endogenous signaling system that is found throughout much of the body (Herkenham et al., 1990) . The two canonical cannabinoid receptors, CB 1 and CB 2 , were identified in the early 1990s (Matsuda et al., 1990; Munro et al., 1993) . Cannabinoids have since been implicated in several major physiological processes (Corcoran et al., 2015; Di Marzo et al., 2015; Alexander, 2016) and cannabinoid receptors remain a promising pharmacological target. However, a persistent hurdle has been the development of ligands that are selective for CB 1 or CB 2 . The widespread distribution of these receptors, particularly of CB 1 , raises the specter of significant off-target actions, particularly if a given drug can engage both receptors. For example, it has been speculated that the analgesic activity of CB 2 agonists in some preclinical pain models may be due to their concurrent activation of CB 1 receptors (Manley et al., 2011) . We have previously reported that JWH015, a compound widely used as a selective CB 2 agonist, is also a potent and efficacious CB 1 agonist (Murataeva et al., 2012) . In the same study we noted that the CB 2 antagonist AM630 also blocks CB 1 signaling at relatively low concentrations. Thus, the identification and careful characterization of cannabinoid receptor ligands is therefore an important task facing the cannabinoid field.
When confronted with two related receptors (e.g., activated by the same endogenous ligands), there are times when it is advantageous not merely to selectively activate one receptor, but to actively block signaling of the other receptor. Compounds with this dual quality are rare and represent an important resource. To date the only well-characterized cannabinoid receptor ligand reported to have this profile is URB447, which is a peripherally restricted CB 1 antagonist, and CB 2 agonist (LoVerme et al., 2009) . Even if such a compound has limited efficacy or potency, it may serve as a lead compound to allow chemists to develop novel variants. To further explore dual action cannabinoid ligands, we have examined the activity of the CB 2 agonists, GW405833 and AM1710, towards CB 1 receptors in autaptic hippocampal neurons as well as in several additional signaling assays using CB 1 -expressing HEK293 or CHO cells.
GW405833 is a compound that was developed as a CB 2 agonist several years ago and has been used as a CB 2 -selective agonist in nearly 20 publications (e.g. (Clayton et al., 2002; LaBuda et al., 2005; Valenzano et al., 2005; Whiteside et al., 2005) ). In radio-ligand binding assays, GW405833 showed high binding affinity for CB2 receptors (CHOK1 cells stably expressing human CB2) with a Ki of 3.92 ± 1.58 nM (Valenzano et al.,2005) . While at CB1 receptors, GW405833 was a low affinity ligand with a Ki of 4772 ± 1676 nM (~1200 fold more selective for CB2 receptors)( CHOK1 cells stably expressing human CB1 receptors) (Valenzano et al., 2005) . Similarly, the structurally distinct AM1710 has been used in several publications as a CB2 agonist, mostly relating to pain research (Khanolkar et al., 2007; Rahn et al., 2011; Deng et al., 2012; Wilkerson et al., 2012; Rahn et al., 2014; Deng et al., 2015) . AM1710 displayed high affinity for CB2 receptors (HEK cells stably expressing human CB2 receptors) with a Ki of 6.7 nM (Khanolkar et al, 2007) and an EC 50 of 11 nM (E max 48 ± 0.3%) to inhibit cAMP accumulation (Dhopeshwarkar and Mackie, 2016) . The affinity of AM1710
for rat CB1 receptors (tested in rat brain synaptosomal membranes) was lower, with a Ki of 360 nM (95% confidence intervals, 330-390) (Khanolkar et al.,2007) (~30 fold more selective for CB2 receptors), . We now report that in addition to CB 2 agonism, GW405833 and AM1710 also serve as antagonists at CB 1 receptors, albeit with distinct pharmacological properties.
METHODS
Hippocampal culture preparation. All procedures used in this study were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health, and approved by the Animal Care Committee of Indiana University and conform to the Guidelines of the National Institutes of Health on the Care and Use of Animals. Mouse hippocampal neurons isolated from the CA1-CA3 region were cultured on microislands as described previously (Furshpan et al., 1976 ; Bekkers site of the recording electrode (the soma). Data were acquired at a sampling rate of 5 kHz. DSE stimuli: After establishing a 10-20 second 0.5 Hz baseline, DSE was evoked by depolarizing to 0 mV for 50 msec, 100 msec, 300 msec, 500 msec, 1 sec, 3 sec and 10 sec, followed in each case by resumption of a 0.5 Hz stimulus protocol for 20-80+ seconds, allowing EPSCs to recover to baseline values. This approach allowed us to determine the sensitivity of the synapses to DSE induction. To allow comparison, baseline values (prior to the DSE stimulus) are normalized to one. DSE inhibition values are presented as fractions of 1, i.e. a 50% inhibition from the baseline response is 0.50 ± standard error of the mean.
The x-axis of DSE depolarization-response curves are log-scale seconds of the duration of the depolarization used to elicit DSE.
Depolarization response curves are obtained to determine pharmacological properties of endogenous 2-AG signaling by depolarizing neurons for progressively longer durations (50 msec, 100 msec, 300 msec, 500 msec, 1 sec, 3 sec and 10 sec). The data are fitted with a nonlinear regression, allowing calculation of an ED 50 , the effective dose or duration of depolarization at which a 50% inhibition is achieved. Statistical significance in these curves is based on non-overlapping 95% confidence intervals.
On-cell Western for receptor internalization
The internalization of the receptor was measured using an on-cell Western assay (Daigle et al., 2008) . Briefly, HA-CB 1 expressing human embryonic kidney (HEK) cells were grown to 95% confluence in DMEM + 10% FBS + 0.5% Pen/Strep (Daigle et al., 2008) . Cells were washed once with HEPES buffered saline (HBS)/bovine serum albumen (BSA) (BSA @ 0.08 mg/ml) 200μL per well. Drugs in HBS/BSA were applied at the indicated concentrations to cells and were incubated for indicated amount of time at 37°C. Cells were then fixed with 4% PFA for 20 minutes and washed 4 times (200μl per well) with tris-buffered saline (TBS). Blocking buffer (Odyssey Blocking buffer, LI-COR, Inc. Lincoln, NE) was applied at 100μl per well for 1h at room temperature. Anti-HA antibody, (mouse monoclonal, 1:500, Covance, Princeton, NJ) diluted in 50:50 Odyssey Blocking Buffer and PBS, was then applied for one hour at room temperature. Following this, the plate was washed 4 times (200 μ l per well) with TBS. Secondary antibody diluted (anti-mouse 680 antibody 1:800, LI-COR, Inc.) in 50:50 blocking buffer and PBS, was then applied for one hour at room temperature. Following this, the plate was washed 4 times (200μl per well) with TBS. The plate was imaged using an Odyssey scanner (700 nm channel, 5.0 intensity, LI-COR, Inc.).
Receptor internalization (expressed in % of basal surface levels) was calculated by dividing average integrated intensities of the drug treated wells by average integrated intensities of vehicle-treated wells. (Binding of HA antibody to wildtype HEK cells was <10% of transfected cells.) All assays were performed in triplicate, unless otherwise mentioned. pERK1/2 assay ERK1/2 activation was measured using an in cell western assay (Wong, 2004; Atwood et al., 2012) . HA-CB 1 expressing human embryonic kidney (HEK) cells were seeded onto poly-D-lysine coated 96-well plates (75,000 cells/well) and grown overnight at 37°C in 5% CO 2 , humidified air. The following day, media was replaced by HBS/BSA (0.2 mg/ml) and cells were challenged with drugs/compounds for 5 minutes, at 37°C in 5% CO 2 , humidified air. After drug incubation, plates were emptied and quickly fixed with ice cold 4% PFA for 20 mins followed by treatment with ice-cold methanol with the plate maintained at -20°C for an additional 15 min. Plates were then washed with TBS/0.1% Triton X-100 for 25 mins (5x 5 min washes). The final wash solution was then replaced by Odyssey blocking buffer (150μL) and incubated further for 90 min with gentle shaking at room temperature. Blocking solution was then removed and replaced with blocking solution containing anti-phospho-ERK1/2 antibody (1:150; Cell Signaling Technology ® , Danvers, MA) and was gently shaken overnight at 4°C.
The next day, plates were washed with TBS containing 0.05% Tween-20 for 25 min (5x 5 min washes). Secondary antibody, donkey anti-rabbit conjugated with IR800 dye (Rockland, Limerick, PA), prepared in blocking solution, was added and gently shaken for 1 hour at room temperature. The plates were then again washed 5 times with TBS/0.05% Tween-20 solution. The plates were patted dry and scanned (700nm channel, 5.5 intensity) using a LI-COR Odyssey scanner. ERK1/2 activation (expressed in %) was calculated by dividing average integrated intensities of the drug treated wells by average integrated intensities of vehicle-treated wells. No primary antibody wells were used to determine nonspecific binding of the secondary antibody. All assays were performed in triplicate, unless otherwise mentioned.
Adenylyl cyclase assay
Adenylyl cyclase assays were optimized using Perkin Elmer's LANCE ® ultra cAMP kit (Catalog # TRF0262, Perkin Elmer, Boston, MA) as per the manufacturer's instruction. All assays were performed at room temperature using 
Schild analysis
Schild plots were generated for internalization assays by employing the method of Schild (Schild, 1947; Arunlakshana and Schild, 1959; Wyllie and Chen, 2007) . We found that while GW405833 did not directly inhibit neurotransmission ( Fig.   1A -B, relative EPSC charge after 10μM GW405833: 1.02 ± 0.02, n=4), it did interfere with CB 1 -mediated DSE in a concentration-dependent manner with an IC 50 of 2.6μM ( Fig. 1C-D) . Similarly, AM1710 did not directly inhibit neurotransmission ( Fig internalization data it appears that GW405833 is an efficacious and moderately potent antagonist at rodent CB 1 receptors.
To explore the nature of the antagonism between GW405833 and CP55940 at CB 1 we tested internalization responses for a range of GW405833 and CP55940 concentrations ( Fig. 3D ), sufficient to conduct a Schild analysis. As shown in Figure 3E and Table 1 , the response profile is consistent with non-competitive antagonism.
AM1710 does not internalize CB 1 receptors but antagonizes CP55940-induced internalization in a concentration-dependent manner
Using the same model system, we tested the effect of AM1710 in CB 1 receptor internalization. AM1710 (10μM) slightly internalized CB 1 receptors after a 2-hour period ( Fig. 4A ; surface levels at 120 mins (%): 93 ± 1.5; n=16, p=0.02 by Student's t-test vs. baseline), suggesting AM1710 is a modestly efficacious agonist or for CB 1 receptor internalization. Furthermore, in contrast to GW405833, 10μM AM1710 does not significantly alter the time course of internalization during a two-hour treatment with 100nM CP55940 ( Fig. 4B ; Cell surface levels at 120mins (% of baseline): CP55940 (100nM): 62 ± 8%; CP55940 (100nM) + AM1710 (10μM): 65 ± 6.7% 17; n= 24, p>0.05, 2 way ANOVA). In examining the effects of a range of AM1710 concentrations on CP55940-induced internalization, we found that AM1710 only modestly right-shifted the CP55940 response curve, even at 10μM. 20μM and 30μM AM1710 more substantially shifted the dose response curve for CP55940 ( Fig 4C) .
To explore the nature of the antagonism between AM1710 and CP55940 at CB 1 , we tested this receptor's internalization responses for a range of AM1710 and
, sufficient to conduct a Schild analysis. As shown in Figure 4D and Table 1 , the Schild analysis is consistent with a low affinity (KB ~10 μ M), competitive antagonism.
GW405833 and AM1710 attenuate inhibition of forskolin-stimulated cAMP accumulation by CP55940
We next examined if GW405833 affected forskolin-stimulated cAMP accumulation or its inhibition by CB 1 agonists in HEK cells stably transfected with rCB1. As expected, CP55940 inhibits cAMP accumulation in a concentrationdependent manner (Fig 5A; EC 50 : 9.5 nM, E max (% basal): 45.6 ± 8.3). While GW405833 had no effect on its own, at 1μM it completely blocks adenylyl cyclase inhibition by CP55940 at CP55940 concentrations up to at least 1μM ( Fig   5A) . Increasing concentrations of GW405833 (300 nM, 500 nM and 1 µM) attenuated CP55940-induced inhibition of forskolin-stimulated adenylyl cyclase 
Both GW405833 and AM1710 attenuate CP55940 activation of pERK1/2
Turning to pERK1/2 activation, again using HEK293 cells stably transfected with rCB1, we confirmed that CP55940 activates pERK1/2 in a concentrationdependent manner (Fig. 5C ). As with cAMP experiments, GW405833 has no effect on its own, but at 1μM it completely blocks the effects of CP55940 at CP55940 concentrations up to at least 1μM (Fig. 5C ). Increasing concentrations of GW405833 (300 nM, 500 nM and 1 µM) inhibited CP55940 induced pERK1/2 activation (E max (%basal), (95%CI): CP55940--72% (65-73.4); CP+GW405833(300 nM)--62 (58.5-63.1); CP+GW405833(500 nM)--45 (42.4-48.2). However, GW405833 did not affect the potency of CP55940 in ERK1/2 activation (EC 50 (95%CI): CP55940--9.6 nM (3.9-17.5); CP+GW4059833 (300 nM)--13.1 nM (7.1-21.6); CP+GW405833(500 nM) 15.8 nM(8.3-27.8).
AM1710 also had no effect on its own on pERK1/2 levels at 10μM, but AM1710 at 10μM and 20μM progressively reduced CP55940 activation of ERK1/2 ( . We also tested a 5 minute pretreatment with 5μM and 10μM GW405833, finding that they, too, were without effect (data not shown). Interestingly, the effect of GW405833 on CP55940-mediated arrestin recruitment was time-dependent. Following a twenty minute pretreatment with GW405833, arrestin recruitment by CP55940 was enhanced, (Fig. 6B) . However, for longer GW405833 pretreatments, CP55940 recruitment was similar to recruitment without GW405833, and ultimately, starting at 60 mins of GW405833 pretreatment, CP55940 recruitment of arrestin was inhibited by GW504833 pretreatment (Fig. 6B) . The potentiation was statistically significant at 20 mins as were the inhibitions relative to CP55940 alone at 60 and 90 minutes (p<0.05, 1 way ANOVA with Bonferroni post hoc test). Importantly, arrestin recruitment by GW405833 alone (Fig. 6A) 
it was not observed following 60 minutes of GW405833 treatment ( Fig. 6B; p>0.05, 1 way ANOVA).
To rule explore the possibility of a chemical interaction between CP55940 and GW405833 that may lead to a complex arrestin signaling profile, similar experiments were performed using the cannabinoid receptor agonist, WIN55212-2 (Fig 6C) . Again, GW405833 displayed a profile where it modestly potentiated WIN55212-2 mediated recruitment of arrestin after 20 minutes of treatment AM1710 also modestly recruited arrestin on its own ( Fig. 6D ; E max (% control ):
138 ± 1; p<0.05, t-test vs. baseline), but in contrast to GW405833, five minute pretreatment with AM1710 (10μM and 20μM) reduced the extent of CP55940-mediated arrestin recruitment (Fig. 6D, p<0 .01 for 10μM; p<0.005 for 20μM), without significantly affecting CP55940 potency.
GW405833 and AM1710 attenuate WIN55212-2-induced increases in IP1 levels
We have previously shown that certain CB 1 agonists, especially aminoalkylindoles such as WIN55212-2, can engage CB 1 to activate G q signaling to increase intracellular calcium via activation of phospholipase C and release of Lauckner et al., 2005) . Therefore we tested whether GW405833 and AM1710 affected G q signaling in rCB1-expressing HEK cells. The CB 1 agonist WIN55212-2 increased IP1 levels by ~50% (Fig. 7A) . Pretreatment for 5 mins with 10μM GW405833 fully blocked the WIN55212 increase in IP1 (Fig. 7A) , while GW405833 had no effect on its own. High concentrations of AM1710 alone modestly reduced IP-1 accumulation ( Fig. 7B ; E max (% basal): 81 ± 2, p<0.05, ttest vs. baseline) and, as with GW405833, AM1710 attenuated the increase in IP1 elicited by WIN55212, doing so fully at 20μM (Fig. 7B : E max (% basal) at 20μM: 81 ± 4, p<0.05, t-test vs. WIN55212-2).
DISCUSSION
Our chief finding is that GW405833 and AM1710 are not only CB 2 agonists as previously reported but also interact with CB 1 receptors with important functional consequences. These structurally distinct compounds have differential properties at CB 1 ; most notably our data suggest that GW405833 is a non-competitive antagonist while AM1710 is a competitive antagonist/inverse agonist at the orthosteric site for G protein signaling and a low efficacy agonist for arrestin recruitment and internalization. AM1710 was generally less potent than GW405833, sometimes requiring 20μM concentrations to produce a statistically significant effect. Consistent with this observation was a KB of 10μM in the Schild analysis of internalization. The non-competitive inhibition of CB 1 signaling by GW405833 is consistent between the several systems used: the autaptic neurons that utilize the endogenous cannabinoid, 2-AG, and the cell-based plate assays using transfected cells and synthetic cannabinoids. In contrast, AM1710
showed signs of pathway selectivity, with internalization and arrestin data suggesting that AM1710 is a low potency, low efficacy agonist for these pathways while the cyclase and IP1 data are more consistent with AM1710 being a moderate affinity inverse agonist at these pathways. Thus, the structure of Our Schild analysis suggests that AM1710 is as a low affinity (KB ~10μM) competitive ligand CB1. In contrast, the action of GW405833 appears noncompetitive in nature, suggesting that GW405833 does not bind to the orthosteric site of CB 1 , which is consistent with ligand binding studies, e.g. (Valenzano et al., 2005) . A plausible mechanism is that GW405833 acts at an allosteric site on CB 1 , in that case making it a negative allosteric modulator of CB 1 . Our results do not however rule out indirect action via some other receptor or signaling pathway.
For example, GW405833 has also been reported to serve as a partial agonist at GW405833 was however broadly efficacious, acting as an antagonist in every assay examined (albeit with a time dependency when inhibiting arrestin recruitment).
The interactions of GW405833 with CB 1 -mediated arrestin recruitment are quite intriguing. Brief treatment with GW405833 modestly enhanced arrestin recruitment to the CB 1 receptor both in the presence and absence of CP55940.
A longer treatment with GW405833 further enhanced arrestin recruitment by CP55940. However, by 1 hour this enhancement by GW405833 shifted to a pronounced inhibition. The net inhibitory effect is consistent with the inhibitory actions seen for other signaling pathways. Transitory stimulation of arrestin signaling is also consistent with the observation that the inhibition of CP55940-mediated CB 1 internalization was only evident at 30 minutes post-treatment with GW405833 ( Fig 3C) . This time-dependence of GW405833 effects on arrestin recruitment was notable for several reasons. Based on our initial experiments, we would have concluded that GW405833 had no effect on arrestin recruitment by CP55940 even at 10μM. However that concentration response data was collected with a 5-minute pre-treatment of GW405833 followed by co-treatment with CP55940. : 6 2 -6 9 . 
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